Arch Biopartners Inc ACHFF

Silence

[Arbourmark]

I have been long term holder of ARCH since 2019. I can't be the only investor who is frustrated with the lack of news or updates from management. I believe in the science but the last meaningful news/update was Feb 2022.

Watching paint dry is more exciting then Arch the past 9 months.

[Cb27743]

I am with you and bunch of other investors are as well. I have been with Arch since 2020 and have been very patient this 2022 year. I understand waiting on regulation can test patience in this sector, but If this is a management strategy to stay quiet with 1 annual update, Arch is going to continue to drop in volume and market interest which we have all witnessed this year. This 2022 year was

[Riverfolk]

The phase II clinical trial process averages 3.6 years from planning-execution-data. I am from the school of thought that no news is good news and when material items happen they will be announced. Given the discussed AKI trial is not a COVID trial, new drug would have to be manufactured/trial design completed and applications made to regulators. This is the unsexy part of the biosciences sector

[Cb27743]

River,  What I am referrring to is not creating fluff news from management, but being transparent to the public regarding the current trial (if they can) and completed P2 trial. There must of been atleast 1 material update in the 9 month duration management could of shared to the public regarding the drug status. We understand CATCO is a 3rd party trial with the assistance from Arch, but

[Riverfolk]

I can understand your frustration in a bear market but if there were material changes the company would have to disclose. I am invested in Arch because the company doesn't raise money (Diluting Shareholders) to promote information that is already known to the market. I think other Canadian companies that do not have a current Phase III drug like AGN, APLI, XRTX have shown that it does not grow

[Arbourmark]

Well said.  

[Arbourmark]

Well another week and continued silence from Management. Was CATCO study positive?? Unknown. Study was approved I believe in February. When was the final dosing completed? Are the final results in? Has a independent peer review commenced? Covid 19, RSV are surging around the world, lung inflammation is a concern.  Yes I know kidney inflammation might be their sweet spot but sometimes

[Cb27743]

I hear your frustration,   We are still waiting for reviewed data from their completed 2021 P2 trial which usually takes 6 from what I heard on another market platform. The last update we recieved from Management regarding the P2 trial was August 2021. Unless there is other material updates we are not aware of? We are almost into 2023 and still ghosted. Is this still being reviewed? was the

[Cb27743]

6 months*